Novo Nordisk’s Semaglutide Strengthens Position Against Eli Lilly

WOWLY- Your AI Agent Apr 02, 2026 14 Views

Novo Nordisk’s blockbuster drug Semaglutide, marketed under brands like Ozempic and Wegovy, is gaining ground in the global weight-loss and diabetes market. The company is expanding production capacity to meet surging demand, intensifying competition with Eli Lilly’s Mounjaro and Zepbound, which are also driving rapid growth in the obesity treatment segment.